HealthCor Management L.P. increased its position in Incyte Co. (NASDAQ:INCY) by 125.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,350,000 shares of the biopharmaceutical company’s stock after acquiring an additional 751,450 shares during the quarter. Incyte comprises approximately 4.2% of HealthCor Management L.P.’s holdings, making the stock its 8th biggest position. HealthCor Management L.P. owned about 0.64% of Incyte worth $127,859,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in INCY. Sands Capital Management LLC grew its holdings in Incyte by 8.2% during the 4th quarter. Sands Capital Management LLC now owns 8,191,287 shares of the biopharmaceutical company’s stock valued at $775,797,000 after buying an additional 621,323 shares in the last quarter. Capital International Investors grew its holdings in Incyte by 1.4% during the 3rd quarter. Capital International Investors now owns 6,494,566 shares of the biopharmaceutical company’s stock valued at $758,176,000 after buying an additional 87,369 shares in the last quarter. Geode Capital Management LLC grew its holdings in Incyte by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 1,938,238 shares of the biopharmaceutical company’s stock valued at $183,205,000 after buying an additional 105,692 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Incyte by 0.4% during the 4th quarter. Bank of New York Mellon Corp now owns 1,682,019 shares of the biopharmaceutical company’s stock valued at $159,304,000 after buying an additional 7,463 shares in the last quarter. Finally, Manning & Napier Advisors LLC purchased a new stake in Incyte during the 3rd quarter valued at approximately $125,065,000. 93.58% of the stock is owned by institutional investors.
In other news, EVP Reid M. Huber sold 1,958 shares of Incyte stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $85.55, for a total transaction of $167,506.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David W. Gryska sold 1,952 shares of Incyte stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $85.56, for a total value of $167,013.12. Following the sale, the insider now owns 12,922 shares of the company’s stock, valued at $1,105,606.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,670 shares of company stock valued at $1,489,181. Corporate insiders own 17.70% of the company’s stock.
Shares of Incyte Co. (NASDAQ INCY) opened at $94.23 on Monday. Incyte Co. has a 52-week low of $80.85 and a 52-week high of $153.15. The company has a quick ratio of 3.99, a current ratio of 4.01 and a debt-to-equity ratio of 0.01.
Incyte (NASDAQ:INCY) last released its earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.54. Incyte had a negative return on equity of 11.85% and a negative net margin of 20.38%. The business had revenue of $444.20 million during the quarter, compared to the consensus estimate of $435.23 million. During the same period last year, the company earned $0.05 earnings per share. The business’s revenue for the quarter was up 36.0% compared to the same quarter last year. equities analysts anticipate that Incyte Co. will post -0.28 EPS for the current fiscal year.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.